Here is the AI research roadmap for 2026: how agents that learn, self-correct, and simulate the real world will redefine ...

The K-star opens up on streaming, bold experiments and finding his way back to the stage. Read more at straitstimes.com. Read ...

2025 has come and gone. It was an interesting year and had its fair share of weird Vancouver stories. We’ve gone through some ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

"I only heard about it this morning," Park Hae-soo says. "They briefed me right before this interview. It still hasn't quite ...

I played these 25 cards the most and built so many decks around them — or at least dreamed how they might function in the ...

TL;DR: The Great Flood starts as a familiar Korean disaster film before mutating into an unsettling sci-fi meditation on emotional optimization and algorithmic storytelling. It’s messy, ...

Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...